Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: INS001
MIFTS: 64

Insulinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Insulinoma

About this section

MalaCards integrated aliases for Insulinoma:

Name: Insulinoma 38 12 76 53 59 29 55 6 44 15 73
Islet Cell Adenoma 12 73
Experimental Organism Islet Cell Adenoma Neoplasm 73
Insulin-Producing Tumor of Islet Cells 12
Adenoma Islet Cell 55
Islet Cell Tumor 73

Characteristics:

Orphanet epidemiological data:

59
insulinoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Ireland),1-9/1000000 (Worldwide),1-9/1000000 (Japan); Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Endocrine diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare gastroenterological diseases
Rare endocrine diseases


Sources

Summaries for Insulinoma

About this section
NIH Rare Diseases : 53 Insulinoma is a type of pancreatic neuroendocrine tumor (pancreatic NET), which refers to a group of rare tumors that form in the hormone-making cells of the pancreas. Insulinomas, specifically, produce too much insulin, a hormone that reduces the level of sugar in the blood by helping it move into cells. As a result, people with insulinomas generally have very low blood sugar levels which can be associated with anxiety, confusion, hunger, a fast heart rate, and sweating. In severe cases, it can lead to seizures, coma or even death. Ninty percent of insulinomas are benign (noncancerous). In most cases, the underlying cause of insulinoma is unknown. However, people with specific genetic syndromes such as multiple endocrine neoplasia type I, Von Hippel-Lindau syndrome, Neurofibromatosis type 1, and tuberous sclerosis are at risk of insulinomas and other endocrine tumors. Treatment generally includes surgery to remove the tumor.

MalaCards based summary : Insulinoma, also known as islet cell adenoma, is related to insulinomatosis and diabetes mellitus and adenoma of the pancreas. An important gene associated with Insulinoma is MEN1 (Menin 1), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Glucose / Energy Metabolism. The drugs Bevacizumab and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, pancreas and pancreatic islet, and related phenotypes are hyperhidrosis and seizures

Disease Ontology : 12 An adenoma that is located in the pancreas and is characterized by overproduction of insulin.

Wikipedia : 76 An insulinoma is a tumor of the pancreas that is derived from beta cells and secretes insulin. It is a... more...

Sources

Related Diseases for Insulinoma

About this section

Diseases related to Insulinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 189)
# Related Disease Score Top Affiliating Genes
1 insulinomatosis and diabetes mellitus 31.3 ABCC8 CHGA INS SCT SST
2 adenoma of the pancreas 31.0 CHGA SST
3 hypoglycemia 30.8 ABCC8 GCG GCK INS
4 multiple endocrine neoplasia, type i 30.5 CHGA INS MEN1 SCT SST
5 glucagonoma 30.5 CHGA SCT SST
6 neuroendocrine tumor 30.3 CHGA INSM1 MEN1 SST
7 hyperinsulinism 30.3 ABCC8 GCK INS SST
8 hyperinsulinemic hypoglycemia 30.2 ABCC8 GCK INS MEN1 SST
9 hyperproinsulinemia 30.2 INS SCT
10 gastrinoma 30.1 CHGA INS MEN1 SCT SST
11 zollinger-ellison syndrome 29.9 CHGA MEN1 SCT SST
12 duodenal ulcer 29.8 INS SCT SST
13 islet cell tumor 29.7 CHGA IAPP INS MEN1 SST
14 carcinoid syndrome 29.7 CHGA MEN1 SST
15 glucose intolerance 29.6 GCG GCK INS
16 small cell cancer of the lung 29.6 CHGA INSM1 SST
17 dumping syndrome 29.6 GCG INS SCT SST
18 diabetes mellitus, noninsulin-dependent 29.0 ABCC8 GCG GCK GLP1R IAPP INS
19 hyperglycemia 28.7 ABCC8 GCG GCK GLP1R IAPP INS
20 diabetes mellitus 28.6 ABCC8 GCG GCK GLP1R IAPP INS
21 insulinoma tumor suppressor gene locus 12.2
22 metastatic insulinoma 12.2
23 adult-onset non-insulinoma persistent hyperinsulinemic hypoglycemia 12.0
24 pancreatic neuroendocrine tumor 11.4
25 multiple endocrine neoplasia 10.5
26 epilepsy 10.3
27 microinvasive cervical squamous cell carcinoma 10.3 INSM1 PTPRN
28 fallopian tube endometrioid adenocarcinoma 10.3 INSM1 PTPRN
29 duodenal somatostatinoma 10.2 INS SST
30 postgastrectomy syndrome 10.2 INS SST
31 postural hypotension 10.2 INS SST
32 pancreatic gastrinoma 10.2 MEN1 SCT
33 pancreatic somatostatinoma 10.2 MEN1 SST
34 fallopian tube adenocarcinoma 10.2 INSM1 PTPRN
35 intestinal neuroendocrine benign tumor 10.2 MEN1 SCT
36 type 1 diabetes mellitus 7 10.2 INS PTPRN
37 small intestine neuroendocrine neoplasm 10.2 MEN1 SCT
38 hormone producing pituitary cancer 10.2 MEN1 SST
39 pancreatic endocrine carcinoma 10.2 INS SST
40 type 1 diabetes mellitus 15 10.2 GCG INS
41 pituitary gland disease 10.2 INS MEN1 SST
42 pancreatic agenesis 1 10.2 PDX1 SCT
43 gastrointestinal neuroendocrine benign tumor 10.2 CHGA SST
44 acromegaly 10.2 INS MEN1 SST
45 hyperinsulinemic hypoglycemia, familial, 7 10.2 GCG INS
46 autosomal genetic disease 10.2 GCK INS MEN1
47 type 1 diabetes mellitus 13 10.2 INS PTPRN
48 gastrointestinal neuroendocrine tumor 10.2 CHGA SST
49 gastric neuroendocrine neoplasm 10.2 CHGA SST
50 maturity-onset diabetes of the young, type 9 10.1 GCG INS

Graphical network of the top 20 diseases related to Insulinoma:



Diseases related to Insulinoma
Sources

Symptoms & Phenotypes for Insulinoma

About this section

Human phenotypes related to Insulinoma:

59 32 (show all 34)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperhidrosis 59 32 hallmark (90%) Very frequent (99-80%) HP:0000975
2 seizures 59 32 hallmark (90%) Very frequent (99-80%) HP:0001250
3 tremor 59 32 hallmark (90%) Very frequent (99-80%) HP:0001337
4 fatigue 59 32 occasional (7.5%) Occasional (29-5%) HP:0012378
5 abnormality of vision 59 32 occasional (7.5%) Occasional (29-5%) HP:0000504
6 generalized muscle weakness 59 32 frequent (33%) Frequent (79-30%) HP:0003324
7 hearing abnormality 59 32 occasional (7.5%) Occasional (29-5%) HP:0000364
8 anxiety 59 32 occasional (7.5%) Occasional (29-5%) HP:0000739
9 paresthesia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003401
10 neuroendocrine neoplasm 59 32 occasional (7.5%) Occasional (29-5%) HP:0100634
11 coma 59 32 occasional (7.5%) Occasional (29-5%) HP:0001259
12 hyperinsulinemic hypoglycemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0000825
13 zollinger-ellison syndrome 59 32 frequent (33%) Frequent (79-30%) HP:0002044
14 pituitary prolactin cell adenoma 59 32 frequent (33%) Frequent (79-30%) HP:0006767
15 fasting hyperinsulinemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0008283
16 increased body weight 59 32 frequent (33%) Frequent (79-30%) HP:0004324
17 insomnia 59 32 occasional (7.5%) Occasional (29-5%) HP:0100785
18 lethargy 59 32 occasional (7.5%) Occasional (29-5%) HP:0001254
19 polyphagia 59 32 frequent (33%) Frequent (79-30%) HP:0002591
20 recurrent hypoglycemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001988
21 neoplasm of the adrenal gland 59 32 occasional (7.5%) Occasional (29-5%) HP:0100631
22 transient global amnesia 59 32 hallmark (90%) Very frequent (99-80%) HP:0010534
23 palpitations 59 32 hallmark (90%) Very frequent (99-80%) HP:0001962
24 nonketotic hypoglycemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001958
25 reactive hypoglycemia 59 32 frequent (33%) Frequent (79-30%) HP:0012051
26 abnormal rapid eye movement sleep 59 32 occasional (7.5%) Occasional (29-5%) HP:0002494
27 abnormality of pain sensation 59 32 occasional (7.5%) Occasional (29-5%) HP:0010832
28 primary hyperparathyroidism 59 32 frequent (33%) Frequent (79-30%) HP:0008200
29 abnormality of the pancreatic islet cells 59 32 hallmark (90%) Very frequent (99-80%) HP:0006476
30 fluctuations in consciousness 59 32 frequent (33%) Frequent (79-30%) HP:0007159
31 behavioral abnormality 59 Frequent (79-30%)
32 reduced consciousness/confusion 59 Frequent (79-30%)
33 hyperinsulinemia 59 Very frequent (99-80%)
34 abnormality of higher mental function 59 Occasional (29-5%)

MGI Mouse Phenotypes related to Insulinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.9 ABCC8 CHGA GCK GLP1R INS INSM1
2 growth/size/body region MP:0005378 9.7 CHGA GCK GLP1R IAPP INS INSM1
3 homeostasis/metabolism MP:0005376 9.5 ABCC8 CHGA GCK GLP1R IAPP INS
Sources

Drugs & Therapeutics for Insulinoma

About this section

Drugs for Insulinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
2
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
3
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
4
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
5
leucovorin Approved Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 6006 143
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
8 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 59763-91-6
9 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
10 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
11 Antimetabolites Phase 2, Phase 3,Phase 1
12 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
13 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
14 Immunologic Factors Phase 2, Phase 3,Phase 1
15 Vitamin B9 Phase 2, Phase 3
16 Folate Phase 2, Phase 3
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
18 Hormone Antagonists Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
19 Hormones Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
20 Central Nervous System Depressants Phase 3,Not Applicable
21 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
22 Calcimimetic Agents Phase 3
23 Calcium, Dietary Phase 3,Phase 2,Phase 1
24 Cinacalcet Hydrochloride Phase 3
25 Cola Phase 3,Phase 2,Phase 1
26 Peripheral Nervous System Agents Phase 3
27 Analgesics, Opioid Phase 3
28 Narcotics Phase 3
29 Anesthetics Phase 3
30 Anesthetics, Intravenous Phase 3
31 Analgesics Phase 3
32 Adjuvants, Anesthesia Phase 3
33 Anesthetics, General Phase 3
34
Exenatide Approved, Investigational Phase 1, Phase 2,Phase 2,Early Phase 1,Not Applicable 141758-74-9 15991534
35
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
36
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
37
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
38
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
39
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
40
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
41
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
42
Pancrelipase Approved, Investigational Phase 2,Phase 1,Not Applicable 53608-75-6
43
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
44
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
45
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
46
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
47
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
48
Melphalan Approved Phase 2 148-82-3 4053 460612
49
Glycerol Approved, Investigational Phase 2,Not Applicable 56-81-5 753
50
Somatostatin Approved, Investigational Phase 2,Phase 1 51110-01-1, 38916-34-6 53481605

Interventional clinical trials:

(show top 50) (show all 53)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
2 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Effect of Gelofusine on GLP1-receptor Imaging Completed NCT02541734 Phase 1, Phase 2 Gelofusine;Placebo
5 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
6 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
7 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
8 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
9 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
10 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
11 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
12 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
13 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
14 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
15 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Active, not recruiting NCT02259725 Phase 2 regorafenib
16 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
17 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 capecitabine;temozolomide
18 Reversing Type 1 Diabetes After it is Established Active, not recruiting NCT01106157 Phase 1, Phase 2 Anti-Thymocyte Globin (ATG);Placebo;Pegylated GCSF
19 Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes Active, not recruiting NCT00336674 Phase 2
20 68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH Enrolling by invitation NCT03189953 Phase 1, Phase 2
21 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
22 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2 everolimus
23 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2 Everolimus
24 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
25 Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy Terminated NCT01056601 Phase 2 Bortezomib;Panobinostat
26 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
27 Pasireotide in Hyperinsulinemic Hypoglycemia Withdrawn NCT03053284 Phase 2 Pasireotide 0.6Mg Solution for Injection;Saline Solution
28 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2 dovitinib lactate
29 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
30 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
31 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
32 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
33 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
34 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
35 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
36 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
37 Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma Recruiting NCT02021604 Phase 1 Fluorodopa F 18
38 Laser Tissue Welding - Distal Pancreatectomy Sealing Study Recruiting NCT03147768 Phase 1
39 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
40 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
41 EUS-guided Ethanol Ablation of an Insulinoma Unknown status NCT02121366 Not Applicable
42 68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis Unknown status NCT02560376 Early Phase 1 68Ga-NOTA-exendin-4
43 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376
44 Laparoscopy to Remove Pancreatic Tumors (Insulinomas) Completed NCT00005910 Not Applicable
45 Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients Completed NCT00937079
46 New Imaging Procedure for the Localisation of Insulinoma Completed NCT02127541 Not Applicable
47 FFA Hypertension and Inflammation in Lean and Obese Subjects Completed NCT00721617 Not Applicable
48 Diagnosing and Treating Low Blood Sugar Levels Recruiting NCT00001276
49 DOTATOC PET/CT for Imaging NET Patients Recruiting NCT03583528
50 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia Available NCT01916148 18F-DOPA

Search NIH Clinical Center for Insulinoma

Cochrane evidence based reviews: insulinoma

Sources

Genetic Tests for Insulinoma

About this section

Genetic tests related to Insulinoma:

# Genetic test Affiliating Genes
1 Insulinoma 29
Sources

Anatomical Context for Insulinoma

About this section

MalaCards organs/tissues related to Insulinoma:

41
Pancreas, Pancreatic Islet, Liver, Heart, Testes, Pituitary, Lung

The Foundational Model of Anatomy Ontology organs/tissues related to Insulinoma:

19
The Pancreas
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Insulinoma:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Islets of Langerhans Mature Beta Cells Affected by disease
Sources

Publications for Insulinoma

About this section

Articles related to Insulinoma:

(show top 50) (show all 1246)
# Title Authors Year
1
Characterization of Transplantable Insulinoma Cells. ( 30535698 )
2019
2
Minimally Invasive Versus Open Treatment for Benign Sporadic Insulinoma Comparison of Short-Term and Long-Term Outcomes. ( 29691623 )
2018
3
Incidence and management of postoperative hyperglycemia in patients undergoing insulinoma resection. ( 29923016 )
2018
4
Probing the Effect of Physiological Concentrations of IL-6 on Insulin Secretion by INS-1 832/3 Insulinoma Cells under Diabetic-Like Conditions. ( 29966345 )
2018
5
Glucose Management during Insulinoma Resection Using Real-Time Subcutaneous Continuous Glucose Monitoring. ( 29977620 )
2018
6
<i>Nfe2l1-</i> silenced insulinoma cells acquire aggressiveness and chemoresistance. ( 29203613 )
2018
7
Insulinoma presenting with post-prandial hypoglycaemia following fundoplication. ( 29367876 )
2018
8
Insulinoma-associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens. ( 29360191 )
2018
9
Pro-inflammatory cytokines attenuate glucose-stimulated insulin secretion from INS-1E insulinoma cells by restricting mitochondrial pyruvate oxidation capacity - Novel mechanistic insight from real-time analysis of oxidative phosphorylation. ( 29953508 )
2018
10
Insulinoma-Associated Protein 1 Immunostain: A Diagnostic Tool for Pulmonary Small Cell Carcinoma in Cytology. ( 29936498 )
2018
11
Insulinoma-associated 1: A novel nuclear marker in Merkel cell carcinoma (cutaneous neuroendocrine carcinoma). ( 29148079 )
2018
12
Robotic enucleation for pediatric insulinoma with MEN1 syndrome: a case report and literature review. ( 29921249 )
2018
13
Rare malignant insulinoma with multiple liver metastases derived from ectopic pancreas: 3-year follow-up and literature review. ( 29662318 )
2018
14
Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. ( 29885405 )
2018
15
Akt/p27<sup>kip1</sup> Pathway Is Not Involved in Human Insulinoma Tumorigenesis. ( 29853883 )
2018
16
The Effect of Everolimus on Refractory Hypoglycemia in a Patient with Inoperable Metastatic Insulinoma Evaluated by Continuous Glucose Monitoring. ( 29877259 )
2018
17
Screening key candidate genes and pathways involved in insulinoma by microarray analysis. ( 29851790 )
2018
18
Arterial calcium stimulation with hepatic venous sampling predicts the localization and size of the insulinoma as well as postoperative weight loss. ( 29966460 )
2018
19
Notch pathway inhibition targets chemoresistant insulinoma cancer stem cells. ( 29175872 )
2018
20
Utility of contrast-enhanced computed tomography in the evaluation of canine insulinoma location. ( 29806550 )
2018
21
17I^-estradiol protects INS-1 insulinoma cells from mitophagy via G protein-coupled estrogen receptors and the PI3K/Akt signaling pathway. ( 29436590 )
2018
22
Diagnostic challenges in a patient with an occult insulinoma:<sup>68A </sup>Ga-DOTA-exendin-4 PET/CT and <sup>68</sup>Ga-DOTATATE PET/CT. ( 29636947 )
2018
23
Clinical Value of<sup>18</sup>F-FDOPA PET/CT With Contrast Enhancement and Without Carbidopa Premedication in Patients with Insulinoma. ( 29277794 )
2018
24
Insulinoma Masquerading as Transient Neurocognitive Impairment. ( 29753794 )
2018
25
Contrast-enhanced harmonic endoscopic ultrasound: A better choice to guide EUS-FNI for insulinoma. ( 29776875 )
2018
26
An observational analysis of insulinoma from 1 single institution. ( 29319794 )
2018
27
68Ga DOTA-Exendin PET/CT for Detection of Insulinoma in a Patient With Persistent Hyperinsulinemic Hypoglycemia. ( 29877881 )
2018
28
Localisation of occult extra-pancreatic insulinoma using glucagon-like peptide-1 receptor molecular imaging. ( 29314520 )
2018
29
Hypoglycemia caused by insulinoma. A review of a case series treated at a tertiary hospital. ( 29657066 )
2018
30
Hepatobiliary and Pancreatic: Tumor to tumor metastasis from a primary insulinoma to a hepatic adenoma. ( 30191606 )
2018
31
Hyperinsulinemic hypoglycemia without insulinoma: Think of activating glucokinase mutation. ( 29555163 )
2018
32
Hypoglycemia Unawareness in Insulinoma Revealed with Flash Glucose Monitoring Systems. ( 30101920 )
2018
33
Insulinoma: A Rare Cause of Hypoglycemia in Childhood. ( 30237390 )
2018
34
Methadone-Associated Hypoglycemia in Chronic Renal Failure Masquerading as an Insulinoma. ( 29145621 )
2018
35
Successful endoscopic ultrasound-guided ethanol ablation of a symptomatic sporadic insulinoma in a patient with severe comorbidities not suitable for pancreatic surgery. ( 28161372 )
2018
36
Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells. ( 29051320 )
2018
37
Pasireotide for the treatment of refractory hypoglycaemia from malignant insulinoma. ( 29055143 )
2018
38
Insulinoma: A retrospective study analyzing the differences between benign and malignant tumors. ( 29452754 )
2018
39
Streptozotocin-Induced Autophagy Reduces Intracellular Insulin in Insulinoma INS-1E Cells. ( 29485914 )
2018
40
Insulinoma: important in the differential diagnosis of persistent hypoglycaemia unrelated to diabetes. ( 29490216 )
2018
41
Radiosynthesis and evaluation of an 18F-labeled silicon containing exendin-4 peptide as a PET probe for imaging insulinoma. ( 29503858 )
2018
42
Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review. ( 29949120 )
2018
43
A pediatric case of insulinoma and a novel MEN1 mutation: the efficacy of the combination therapy of diazoxide and cornstarch. ( 30083038 )
2018
44
Transformation of a non-secretory neuroendocrine tumor to insulinoma after treatment with Sunitinib: A case report and review of the literature. ( 30089432 )
2018
45
Multiple endocrine neoplasia type 1 presenting with concurrent insulinoma and prolactinoma in early-adolescence. ( 30127804 )
2018
46
Homogenously isoattenuating insulinoma on biphasic contrast-enhanced computed tomography: Little benefits of diffusion-weighted imaging for lesion detection. ( 30127903 )
2018
47
Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections. ( 30154579 )
2018
48
Durable complete response with a short course of streptozotocin plus doxorubicin combination in malignant metastatic insulinoma. ( 30197367 )
2018
49
PEP-1-paraoxonase 1 fusion protein prevents cytokine-induced cell destruction and impaired insulin secretion in rat insulinoma cells. ( 30269741 )
2018
50
Enhanced survival and insulin secretion of insulinoma cell aggregates by incorporating gelatin hydrogel microspheres. ( 30271863 )
2018
Sources

Variations for Insulinoma

About this section

ClinVar genetic disease variations for Insulinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MEN1 NM_000244.3(MEN1): c.371_372delTC (p.Val124Aspfs) deletion Pathogenic GRCh38 Chromosome 11, 64809738: 64809739
2 MEN1 NM_000244.3(MEN1): c.371_372delTC (p.Val124Aspfs) deletion Pathogenic GRCh37 Chromosome 11, 64577210: 64577211
Sources

Expression for Insulinoma

About this section
Search GEO for disease gene expression data for Insulinoma.
Sources

Pathways for Insulinoma

About this section

Pathways related to Insulinoma according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Aldosterone synthesis and secretion 37
Show member pathways
 12.47 ABCC8 GCG GCK GLP1R INS PDX1
2
Glucose / Energy Metabolism 4
12.29 GCG INS PDX1 WFS1
3
Presynaptic function of Kainate receptors 66
Show member pathways
 12.13 GCG GLP1R IAPP SCT
4
Integration of energy metabolism 66
Show member pathways
 12.08 ABCC8 GCG GLP1R INS SLC2A2
5
G alpha (s) signalling events 66
11.87 GCG GLP1R IAPP SCT
6
Hepatic ABC Transporters 64
Show member pathways
 11.76 GCK INS PDX1 SLC2A2
7
Glucagon signaling pathway 37
11.65 GCG GCK SLC2A2
8
Type II diabetes mellitus 37 1
Show member pathways
 11.54 ABCC8 GCK INS PDX1 SLC2A2
9
Regulation of beta-cell development 66
Show member pathways
 11.1 GCK IAPP INS INSM1 PDX1 SLC2A2
10
FOXA2 and FOXA3 transcription factor networks 1
11 ABCC8 GCK INS PDX1 SLC2A2
11
Cori Cycle 1
10.68 INS SLC2A2
Sources

GO Terms for Insulinoma

About this section

Cellular components related to Insulinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 secretory granule GO:0030141 9.33 CHGA PTPRN PTPRN2
2 transport vesicle membrane GO:0030658 9.13 CHGA PTPRN PTPRN2
3 endoplasmic reticulum lumen GO:0005788 9.02 GCG INS MEN1 PTPRN2 WFS1

Biological processes related to Insulinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.85 GCG IAPP INS SCT SST
2 cellular protein metabolic process GO:0044267 9.78 IAPP INS MEN1 WFS1
3 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.7 GCG GLP1R IAPP
4 glucose metabolic process GO:0006006 9.61 GCK INS PDX1
5 cellular glucose homeostasis GO:0001678 9.56 ABCC8 GCK
6 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.55 PDX1 WFS1
7 positive regulation of glycogen biosynthetic process GO:0045725 9.54 GCK INS
8 negative regulation of gluconeogenesis GO:0045721 9.51 GCK INS
9 negative regulation of blood vessel diameter GO:0097756 9.49 CHGA INS
10 glucose homeostasis GO:0042593 9.46 GCK INS PDX1 WFS1
11 insulin secretion involved in cellular response to glucose stimulus GO:0035773 9.4 PTPRN PTPRN2
12 negative regulation of type B pancreatic cell apoptotic process GO:2000675 9.37 PDX1 WFS1
13 regulation of potassium ion transport GO:0043266 9.32 GCK KCNA5
14 detection of glucose GO:0051594 9.26 GCK PDX1
15 type B pancreatic cell differentiation GO:0003309 9.13 INSM1 MEN1 PDX1
16 regulation of insulin secretion GO:0050796 9.1 ABCC8 GCG GCK GLP1R KCNA5 SLC2A2

Molecular functions related to Insulinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.02 GCG IAPP INS SCT SST
Sources

Sources for Insulinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....